http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-066845-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28e3113097dd6d28720572e47f2f2407 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 |
| filingDate | 2008-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e31d7ae22c8e7981bbf4406edb17c86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1ed1c05b458bc8f3926ee182c9ebd31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70f60777c5324fe266eea6f76ca33d6b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30dce28896442ef6c366f94bb4d69959 |
| publicationDate | 2009-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-066845-A1 |
| titleOfInvention | DERIVATIVES OF TRIAZOLOPIRIDINE AND IMIDAZOPIRIDINE A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER |
| abstract | These compounds possess kinase inhibitory activity. Pharmaceutical compound that understands them and their use in the preparation of anti-cancer drugs. Claim 1: A compound characterized by the formula (1), wherein Z1, Z2, Z3 and Z4 show the following combination: (Z1, Z2, Z3, Z4) = (CR4, N, CR5, C), (N, N , CR5, C), (N, C, CR5, N), (S, C, CR5, C) or (S, C, N, C); R1 and R2 are the same or different and each is (1) a hydrogen atom, (2) a halogen atom, (3) a group linked by a carbon atom, (4) a group linked by a nitrogen atom , (5) a group linked by an oxygen atom or (6) a group linked by a sulfur atom; R3 is an amino that optionally has substituents; R4 and R5 are the same or different and each is (1) a hydrogen atom, (2) a halogen atom, (3) a group linked by a carbon atom, (4) a group linked by a nitrogen atom , (5) a group linked by an oxygen atom or (6) a group linked by a sulfur atom; R3 and R4 optionally form a ring that optionally has substituents; a group represented by the formula (2) is a cyclic group that optionally has substituents, with the proviso that (1) when (Z1, Z2, Z3, Z4) = (S, C, CR5, C), the group represented by Formula (2) is a group represented by Formula (3) where R6 is (1 ') an amino, (2') a C1-6 mono-alkylamino, (3 ') a C1-6 di-alkylamino, ( 4 ') a mono (C1-6 alkylcarbonyl) amino that optionally has 1 to 3 halogen atoms, (5') a mono (C3-6-carbonyl) amino, (6 ') a mono (C3- cycloalkenyl) 6-carbonyl) amino, (7 ') a mono (C6-10 -carbonyl) amino mono that optionally has 1 to 3 halogen atoms, (8') a 5 or 6-membered aromatic monocyclic monocyclic heterocyclylcarbonyl which optionally has 1 to 3 substituents selected from (a) a halogen atom, (b) a C1-6 alkyl that optionally has 1 to 3 halogen atoms, (c) a C1-6 alkoxy and (d) a C3 cycloalkyl -6, (9 ') an 8 to 12 membered amino (heterocyclyl-carbonyl fused aromatic carbon) optionally having 1 to 3 substituents selected from (a) a halogen atom, (b) a C1-6 alkyl that optionally has 1 to 3 halogen atoms, (c) a C1-6 alkoxy and (d) a C3-6 cycloalkyl, (10 ') a 3- to 8-membered non-aromatic mono (heterocyclylcarbonyl) amino, (11') a C1-6-carbonylamino monoalkoxy, (12 ') a C1-6-aminocarbonyl alkyl, (13') a di -C 1-6 alkyl aminocarbonyl or (14 ') a nitro, and the B ring is a benzene ring which also optionally has substituents, and (2) when (Z1, Z2, Z3, Z4) = (S, C , N, C), the group represented by formula (2) is an aromatic cyclic group having substituents (which exclude 2-methoxycarbonylamino-6- (4-nitrophenoxy) imidazo [1,2-a] pyridine, 2-methoxycarbonylamino -6- (phenoxy) imidazo [1,2-a] pyridine, 6- (4-acetamidophenoxy) -2-methoxycarbonylaminoimidazo [1,2-a] pyridine, 6- (4-aminophenoxy) -2-methoxycarbonylaminoimidazo [1, 2-a] pyridine and 6- (4- (2-fluoro-5- (trifluoromethyl) phenyl) aminocarbonylamino) phenoxy-2-methoxycarbonylaminoimidazo [1,2-a] pyridine), or a salt of the same. |
| priorityDate | 2007-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.